Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report.
J Med Case Rep
; 17(1): 64, 2023 Feb 24.
Article
in English
| MEDLINE | ID: covidwho-2276510
ABSTRACT
BACKGROUND:
Bamlanivimab and etesevimab had been granted emergency use authorization in children under 12 years who are at risk of progression from mild/moderate coronavirus disease 2019 to severe disease and hospitalization. CASE REPORT We report on a 5-year-old white male with preexisting conditions, predisposing him to severe disease, who developed hypoxia and flushing 3 minutes into his infusion, thus meeting the criteria for anaphylaxis.CONCLUSIONS:
We believe this patient developed either an immunoglobulin E-mediated anaphylactic or a non-immunoglobulin E-mediated anaphylactoid reaction to bamlanivimab and etesevimab, which is an important possibility to consider on administration.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Anaphylaxis
Type of study:
Case report
/
Prognostic study
Limits:
Child
/
Child, preschool
/
Humans
/
Male
Language:
English
Journal:
J Med Case Rep
Year:
2023
Document Type:
Article
Affiliation country:
S13256-023-03779-3
Similar
MEDLINE
...
LILACS
LIS